Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc Ord (OP: AZNCF )

154.72 +0.26 (+0.17%)
Streaming Delayed Price Updated: 10:00 AM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc Ord

< Previous 1 2 3 4 5 6 7 8 Next >
AstraZeneca's Medimmune Terminates DNA Cancer Vaccine Program With Inovio
MedImmune Limited, a unit of AstraZeneca Plc (NASDAQ: AZN), has notified Inovio Pharmaceuticals Inc (NASDAQ: INO) to terminate the DNA cancer vaccine... 
Via Benzinga
AstraZeneca To Offload Some Drug Rights To Covis Pharma For $270M
AstraZeneca Plc (NASDAQ: AZN) will transfer global rights for respiratory medicines Eklira and Duaklir to Covis Pharma Group for $270 million. Covis will also... 
Via Benzinga
AstraZeneca's Imfinzi/Chemo Combo Strikes First Immunotherapy Wins In Bile Duct Cancer Trial
AstraZeneca Plc (NASDAQ: AZN) revealed topline results from the Phase 3 TOPAZ-1 study. Related: AstraZeneca Touts Longest Survival Update In Lung Cancer... 
Via Benzinga
AstraZeneca Pulls Plug On MCL-1 Cancer Drug Trial
AstraZeneca Plc (NASDAQ: AZN) has paused an active Phase 1 trial of AZD5991, a direct inhibitor of MCL-1, citing a potential safety issue. Two years ago, the FDA hit ... 
Via Benzinga
Exposures Product Safety
AstraZeneca's COVID-19 Therapy Hits Goal In Phase 3 Trial
AstraZeneca Plc (NASDAQ: AZN) released top-line data from the TACKLE Phase 3 trial in which its experimental COVID-19 drug has helped cut the risk of severe disease... 
Via Benzinga
Exposures COVID-19
AstraZeneca Seeks Emergency Use Nod For COVID-19 Drug To Prevent Infection
AstraZeneca Plc (NASDAQ: AZN) has filed for an FDA Emergency Use Authorization (EUA) of AZD7442, its long-acting antibody (LAAB) combination, for prophylaxis of... 
Via Benzinga
Exposures COVID-19 Product Safety
EMA's Risk Assessment Committee Finds Link Of Rare Cases Between JNJ COVID-19 Shot, Blood Clots
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) has concluded a possible link to rare cases of venous thromboembolism (VTE) with... 
Via Benzinga
Exposures COVID-19
AstraZeneca COVID-19 Jab Shows 74% Efficacy In US Trial
Reuters reported that large U.S. trial results of AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine demonstrated 74% efficacy at preventing symptomatic disease... 
Via Benzinga
Exposures COVID-19
Adagio's COVID-19 Candidate Shows Prolonged Half-Life, Neutralization At Six Months
Adagio Therapeutics Inc (NASDAQ: ADGI) has announced new data from its COVID-19 antibody program. Related Link: Adagio Therapeutics To Expand Late-Stage... 
Via Benzinga
Exposures COVID-19
AstraZeneca Buys Fortress-Biotech Founded Caelum For $500M
AstraZeneca Plc (NASDAQ: AZN) will take complete control of Caelum Biosciences in a deal worth up to $500 million, sharpening its focus on rare-disease... 
Via Benzinga
AstraZeneca's Saphnelo For Lupus Treatment Approved In Japan
The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved AstraZeneca plc’s (NASDAQ: AZN) Saphnelo (anifrolumab) for systemic lupus... 
Via Benzinga
AstraZeneca, Sputnik Light COVID-19 Vaccine Mix Shows Strong Antibody Growth: Reuters
A small-scale study of AstraZeneca Plc (NASDAQ: AZN) COVID-19 combined with Sputnik Light vaccines has shown robust antibody growth in most of the study's... 
Via Benzinga
Exposures COVID-19
AstraZeneca - Merck's Lynparza Delays Disease Progression In Prostate Cancer Patients
AstraZeneca Plc (NASDAQ: AZN) has reported high-level results from the PROpel Phase 3 trial of Lynparza (olaparib) in metastatic castration-resistant prostate... 
Via Benzinga
AstraZeneca Invests In Imperial College's Self-Amplifying RNA Tech
AstraZeneca Plc (NASDAQ: AZN) struck a deal with a startup for a self-amplifying RNA (saRNA) therapeutics platform developed at Imperial College London. Under the... 
Via Benzinga
AstraZeneca To Inject $360M In Irish API Manufacturing Site
AstraZeneca plc (NASDAQ: AZN) will invest $360 million to develop a manufacturing facility in Ireland to produce active pharmaceutical ingredients (APIs). The... 
Via Benzinga
AstraZeneca's Enhertu Posts Substantial Clinical Benefit Over Roche's Kadcyla In Breast Cancer Trials
AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo's (OTC: DSNKY) Enhertu have shown some striking data in late-stage breast cancer trials and early solid tumor... 
Via Benzinga
AstraZeneca Touts Longest Survival Update In Lung Cancer Setting With Imfinzi/Chemo Data
AstraZeneca plc (NASDAQ: AZN) announced updated data from the CASPIAN Phase 3 trial of Imfinzi (durvalumab) combined with a choice of chemotherapies etoposide plus... 
Via Benzinga
AstraZeneca's Imfinzi / Tremelimumab Combo Regime Shows Survival Benefit In Lung Cancer Settings
POSEIDON Phase 3 trial results showed AstraZeneca Plc's (NASDAQ: AZN) Imfinzi (durvalumab), tremelimumab, and chemotherapy, extended survival in lung cancer... 
Via Benzinga
Amgen, AstraZeneca Tout Additional Data From Asthma Trial With Tezepelumab
Amgen Inc (NASDAQ: AMGN) announced new data from the NAVIGATOR Phase 3 trial evaluating tezepelumab in patients who also have nasal polyps, a common complication... 
Via Benzinga
Why Innate Pharma Shares Are Rising On Friday?
Innate Pharma SA (NASDAQ:IPHA) stock closed a... 
Via Benzinga
AstraZeneca's Ultomiris Scores European Nod For Rare Blood Disorder In Kids, Adolescents
The European Commission has approved Alexion's Ultomiris (ravulizumab) paroxysmal nocturnal hemoglobinuria (PNH) in children (with a bodyweight of 10 kg or above)... 
Via Benzinga
AstraZeneca, EU Reach Settlement On COVID-19 Vaccine Delivery
AstraZeneca Plc (NASDAQ: AZN) and the European Commission have settled on the delivery of pending COVID-19 vaccine doses by the Company. The agreement ends legal... 
Via Benzinga
Exposures COVID-19
AstraZeneca's Drug Shows Promise In Copper Build-Up Genetic Disease
AstraZeneca plc (NASDAQ: AZN) reported high-level results from the FoCus Phase 3 trial evaluating ALXN1840 in Wilson disease. The study met the primary goal of... 
Via Benzinga
Why Did AstraZeneca's Alexion Stop Amyotrophic Lateral Sclerosis Trial?
AstraZeneca Inc's (NASDAQ: AZN) newly acquired Alexion division will stop developing a treatment for the neurological disorder amyotrophic lateral sclerosis (ALS) due to... 
Via Benzinga
AstraZeneca's COVID-19 Antibody Cuts Risk Of Symptomatic Disease By 77%
A new coronavirus antibody treatment developed by AstraZeneca plc (NASDAQ: AZN) reduced the risk of developing the symptomatic disease by 77% compared to placebo.... 
Via Benzinga
Exposures COVID-19
Facebook Blocks Russia Based Ad Agency Behind COVID-19 Vaccine Smear Campaign
Facebook Inc (NASDAQ: FB) removed multiple accounts linked to a mysterious advertising agency operating out of Russia that sought to pay social media influencers to deride... 
Via Benzinga
Exposures COVID-19
Britain Study Shows Restricted Use Of AstraZeneca COVID-19 Shot Associated With No Clot Cases: Reuters
Following a decision to restrict the use of University of Oxford / AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine in those under the age of 40 years, no new cases... 
Via Benzinga
Exposures COVID-19
AstraZeneca's Forxiga Wins European Approval For Chronic Kidney Disease
The European Union has approved AstraZeneca plc’s (NASDAQ: AZN) Forxiga (dapagliflozin) for chronic kidney disease (CKD) in adults with and without type-2... 
Via Benzinga
AstraZeneca' Saphnelo Wins FDA Nod For Systemic Lupus Erythematosus, Marking New Treatment Approval In 10 Years
The FDA has approved AstraZeneca Plc's (NASDAQ: AZN) Saphnelo (anifrolumab-fnia) for adult patients with moderate to severe systemic lupus erythematosus (SLE)... 
Via Benzinga
Exposures Product Safety
AstraZeneca Looking At Potential Options for COVID-19 Vaccine Business: Reuters
AstraZeneca plc (NASDAQ: AZN) is reportedly exploring its options for the future of its COVID-19 vaccine business. The Company expects clarity on the matter by the... 
Via Benzinga
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.